| [1] |
Nakagawa K, Sho M, Fujishiro M, et al. Clinical practice guidelines for duodenal cancer 2021[J]. J Gastroenterol, 2022, 57(12): 927-941. DOI: 10.1007/s00535-022-01919-y.
pmid: 36260172
|
| [2] |
de Back T, Nijskens I, Schafrat P, et al. Evaluation of systemic treatments of small intestinal adenocarcinomas: a systematic review and meta-analysis[J]. JAMA Netw Open, 2023, 6(2): e230631. DOI: 10.1001/jamanetworkopen.2023.0631.
|
| [3] |
Khosla D, Dey T, Madan R, et al. Small bowel adenocarcinoma: an overview[J]. World J Gastrointest Oncol, 2022, 14(2): 413-422. DOI: 10.4251/wjgo.v14.i2.413.
|
| [4] |
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14): 1273-1281. DOI: 10.1056/NEJMoa0908721.
|
| [5] |
Oh DY, He AR, Qin SK, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer[J]. NEJM Evid, 2022, 1(8): EVIDoa2200015. DOI: 10.1056/EVIDoa2200015.
|
| [6] |
Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2023, 401(10391): 1853-1865. DOI: 10.1016/S0140-6736(23)00727-4.
pmid: 37075781
|
| [7] |
Zhang ZF, Liu X, Chen DW, et al. Radiotherapy combined with immunotherapy: the dawn of cancer treatment[J]. Signal Transduct Target Ther, 2022, 7(1): 258. DOI: 10.1038/s41392-022-01102-y.
|
| [8] |
Kumar R, Kim J, Deek MP, et al. Combination of immunotherapy and radiation therapy in gastrointestinal cancers: an appraisal of the current literature and ongoing research[J]. Curr Oncol, 2023, 30(7): 6432-6446. DOI: 10.3390/curroncol30070473.
pmid: 37504333
|
| [9] |
Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study[J]. Lancet Oncol, 2017, 18(9): 1182-1191. DOI: 10.1016/S1470-2045(17)30422-9.
pmid: 28734759
|
| [10] |
Finn RS, Ikeda M, Zhu AX, et al. Phase Ⅰb study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38(26): 2960-2970. DOI: 10.1200/JCO.20.00808.
|
| [11] |
崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552. DOI: 10.3760/cma.j.cn371439-20230612-00105.
|
| [12] |
Kavanagh BD, Pan CC, Dawson LA, et al. Radiation dose-volume effects in the stomach and small bowel[J]. Int J Radiat Oncol Biol Phys, 2010, 76(3 Suppl): S101-S107. DOI: 10.1016/j.ijrobp.2009.05.071.
|
| [13] |
Broggi S, Passoni P, Tiberio P, et al. Stomach and duodenum dose-volume constraints for locally advanced pancreatic cancer patients treated in 15 fractions in combination with chemotherapy[J]. Front Oncol, 2023, 12: 983984. DOI: 10.3389/fonc.2022.983984.
|
| [14] |
Ayasun R, Ozer M, Sahin I. The role of HER2 status in the biliary tract cancers[J]. Cancers (Basel), 2023, 15(9): 2628. DOI: 10.3390/cancers15092628.
|
| [15] |
Shin JW, Kim S, Ha S, et al. The HER2 S310F mutant can form an active heterodimer with the EGFR, which can be inhibited by cetuximab but not by trastuzumab as well as pertuzumab[J]. Biomolecules, 2019, 9(10): 629. DOI: 10.3390/biom9100629.
|
| [16] |
Ten Haaft BH, Pedregal M, Prato J, et al. Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: current advancements and future perspectives[J]. Eur J Cancer, 2024, 199: 113564. DOI: 10.1016/j.ejca.2024.113564.
|
| [17] |
邓莉莉, 段星宇, 李保中. HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 751-757. DOI: 10.3760/cma.j.cn371439-20230911-00141.
|
| [18] |
Camera S, Rimini M, Foti S, et al. Anti-human epidermal growth factor receptor-2 therapies in biliary tract cancers: a meta-analysis on disease location, human epidermal growth factor receptor-2 status, and survival outcomes[J]. Oncology, 2025, 26: 1-13. DOI: 10.1159/000545308.
|
